Selected Publications

Academic Article

Year Title Altmetric
2023 RNA regulation of inflammatory responses in glia and its potential as a therapeutic target in central nervous system disordersGlia.  71:485-508. 2023
2022 Inhibition of the RNA Regulator HuR by SRI-42127 Attenuates Neuropathic Pain After Nerve Injury Through Suppression of Neuroinflammatory ResponsesNeurotherapeutics.  19:1649-1661. 2022
2022 Smad8 Is Increased in Duchenne Muscular Dystrophy and Suppresses miR-1, miR-133a, and miR-133bInternational Journal of Molecular Sciences.  23. 2022
2022 The versatile role of HuR in Glioblastoma and its potential as a therapeutic target for a multi-pronged attackAdvanced Drug Delivery Reviews.  181. 2022
2022 SRI-42127, a novel small molecule inhibitor of the RNA regulator HuR, potently attenuates glial activation in a model of lipopolysaccharide-induced neuroinflammationGlia.  70:155-172. 2022
2021 FGF23, a novel muscle biomarker detected in the early stages of ALSScientific Reports.  11. 2021
2021 The pathogenic role of c-Kit+ mast cells in the spinal motor neuron-vascular niche in ALSActa Neuropathologica Communications.  9. 2021
2021 Fat mass loss correlates with faster disease progression in amyotrophic lateral sclerosis patients: Exploring the utility of dual-energy xray absorptiometry in a prospective studyPLoS One.  16. 2021
2021 Targeting the HuR oncogenic role with a new class of cytoplasmic dimerization inhibitorsCancer Research.  81:2220-2233. 2021
2021 13109 Phosphorylation state of Myristoylated Alanine-Rich C-Kinase Substrate Effector Domain mimetics determines its cytotoxicity in glioblastoma and macrophage modelJournal of Clinical and Translational Science.  5:1-1. 2021
2021 A Nitroalkene Benzoic Acid Derivative Targets Reactive Microglia and Prolongs Survival in an Inherited Model of ALS via NF-κB InhibitionNeurotherapeutics.  18:309-325. 2021
2020 Wnt antagonist FRZB is a muscle biomarker of denervation atrophy in amyotrophic lateral sclerosisScientific Reports.  10. 2020
2020 Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosisVaccine Reports.  6. 2020
2020 Schwann cells orchestrate peripheral nerve inflammation through the expression of CSF1, IL-34, and SCF in amyotrophic lateral sclerosisGlia.  68:1165-1181. 2020
2020 The vitamin D activator CYP27B1 is upregulated in muscle fibers in denervating disease and can track progression in amyotrophic lateral sclerosis 2020
2019 Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growthGlia.  67:2424-2439. 2019
2019 CD34 identifies a subset of proliferating microglial cells associated with degenerating motor neurons in ALSInternational Journal of Molecular Sciences.  20. 2019
2019 Quality of Care for Veterans With In-Hospital Stroke.Federal practitioner : for the health care professionals of the VA, DoD, and PHS.  36:365-369. 2019
2019 Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cellsCancer Biology and Therapy.  20:979-988. 2019
2018 Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALSJCI Insight.  3. 2018
2018 Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosisNeurobiology of Disease.  114:85-94. 2018
2018 Characterization of the transient middle cerebral artery occlusion model of ischemic stroke in a HuR transgenic mouse line.Data in Brief.  16:1083-1090. 2018
2017 Transgenic expression of HuR increases vasogenic edema and impedes functional recovery in rodent ischemic strokeNeuroscience Letters.  661:126-131. 2017
2017 Hu antigen R (HuR) multimerization contributes to glioma disease progressionJournal of Biological Chemistry.  292:16999-17010. 2017
2017 Astrocytic expression of the RNA regulator HuR accentuates spinal cord injury in the acute phaseNeuroscience Letters.  651:140-145. 2017
2017 HuR promotes the molecular signature and phenotype of activated microglia: Implications for amyotrophic lateral sclerosis and other neurodegenerative diseasesGlia.  65:945-963. 2017
2017 RNA Binding Protein Human Antigen R is Translocated in Astrocytes following Spinal Cord Injury and Promotes the Inflammatory ResponseJournal of Neurotrauma.  34:1249-1259. 2017
2015 Transforming growth factor beta (TGF-β) is a muscle biomarker of disease progression in ALS and correlates with smad expressionPLoS One.  10. 2015
2014 Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: Implications for amyotrophic lateral sclerosisJournal of Biological Chemistry.  289:31792-31804. 2014
2014 Smads as muscle biomarkers in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology.  1:778-787. 2014
2014 Role of KSRP in control of type i interferon and cytokine expressionJournal of Interferon and Cytokine Research.  34:267-274. 2014
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitroJournal of Neuro-Oncology.  118:61-72. 2014
2013 Epidemiological features of amyotrophic lateral sclerosis in a large clinic-based African American populationAmyotrophic lateral sclerosis & frontotemporal degeneration.  14:334-337. 2013
2013 Mutant tristetraprolin: A potent inhibitor of malignant glioma cell growthJournal of Neuro-Oncology.  113:195-205. 2013
2013 Electromyography tests in patients with implanted cardiac devices are safe regardless of magnet placementMuscle and Nerve.  47:17-22. 2013
2012 KSRP: A checkpoint for inflammatory cytokine production in astrocytesGlia.  60:1773-1784. 2012
2012 Phosphoregulation of the RNA-binding protein Hu antigen R (HuR) by Cdk5 affects centrosome functionJournal of Biological Chemistry.  287:32277-32287. 2012
2012 Sex hormone-dependent attenuation of EAE in a transgenic mouse with astrocytic expression of the RNA regulator HuRJournal of Neuroimmunology.  246:34-37. 2012
2011 The RNA-binding protein HuR promotes glioma growth and treatment resistanceMolecular Cancer Research.  9:648-659. 2011
2011 Dermatomyositis and concomitant overlap myasthenic syndrome: A rare presentationJournal of the American Academy of Dermatology.  65. 2011
2009 Amyotrophic lateral sclerosis-linked mutant SOD1 sequesters Hu antigen R (HuR) and TIA-1-related protein (TIAR). Implications for impaired post-transcriptional regulation of vascular endothelial growth factorJournal of Biological Chemistry.  284:33989-33998. 2009
2009 Mutant copper-zinc superoxide dismutase associated with amyotrophic lateral sclerosis binds to adenine/uridine-rich stability elements in the vascular endothelial growth factor 3′-untranslated regionJournal of Neurochemistry.  108:1032-1044. 2009
2008 Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cellsJournal of Cellular Physiology.  217:172-183. 2008
2008 Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cellsCancer Research.  68:674-682. 2008
2007 Mutant Cu/Zn-superoxide dismutase associated with amyotrophic lateral sclerosis destabilizes vascular endothelial growth factor mRNA and downregulates its expression 2007
2005 The ELAV RNA-stability factor HuR binds the 5′-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translationNucleic Acids Research.  33:2962-2979. 2005
2005 Docking and rolling, a model of how the mitotic motor Eg5 worksJournal of Biological Chemistry.  280:35684-35695. 2005
2005 Novel DNA-binding properties of the RNA-binding protein TIARNucleic Acids Research.  33:4507-4518. 2005
2005 IL-1β induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3′ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIARInternational Journal of Cancer.  113:911-919. 2005
2005 Anti-Hu antibody neuropathy: A clinical, electrophysiological, and pathological studyClinical Neurophysiology.  116:28-34. 2005
2003 Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuRCancer Research.  63:4181-4187. 2003
2003 Stepping and stretching. How kinesin uses internal strain to walk processively.Journal of Biological Chemistry.  278:18550-18556. 2003
2002 Measuring kinesin's first stepJournal of Biological Chemistry.  277:36731-36739. 2002
2002 Human cytomegalovirus infection and expression in human malignant gliomaCancer Research.  62:3347-3350. 2002
2002 Porphyria presenting with bilateral radial motor neuropathy: Evidence of a novel gene mutationNeurology.  58:1118-1121. 2002
2001 Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells.Journal of Clinical Investigation.  108:1657-1665. 2001
2001 ATP Reorients the Neck Linker of Kinesin in Two Sequential StepsJournal of Biological Chemistry.  276:40167-40174. 2001
2001 HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAsCancer Research.  61:2154-2161. 2001
2001 Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cellsJournal of Clinical Investigation.  108:1657-1665. 2001
2000 Analysis of the 5' end of the mouse Elavl1 (mHuA) gene reveals a transcriptional regulatory element and evidence for conserved genomic organizationGene.  242:125-131. 2000
2000 RNA-binding analyses of HuC and HuD with the VEGF and c-myc 3'-untranslated regions using a novel ELISA-based assay.Nucleic Acids Research.  28. 2000
1999 Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological diseaseJournal of Autoimmunity.  13:435-443. 1999
1998 HuR, a novel target of anti-Hu antibodies, is expressed in non-neural tissuesJournal of Neuroimmunology.  92:152-159. 1998
1998 Charcot-Marie-Tooth phenotype produced by a duplicated PMP22 gene as part of a 17p trisomy-translocation to the X chromosome. 1998
1998 Localization of HuC (ELAVL3) to chromosome 19p13.2 by fluorescence in situ hybridization utilizing a novel tyramide labeling techniqueGenomics.  53:296-299. 1998
1997 Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features.Clinical Cancer Research.  3:1859-1865. 1997
1997 Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype.International Journal of Cancer.  74:378-382. 1997
1996 Localization of human elav-like neuronal protein 1 (Hel-N1) on chromosome 9p21 by chromosome microdissection polymerase chain reaction and fluorescence in situ hybridizationGenomics.  36:189-191. 1996
1996 Cloning the 5' flanking region of neuron-specific Hel-N1: evidence for positive regulatory elements governing cell-specific transcription.Brain Research.  723:141-147. 1996
1996 Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma.Annals of Neurology.  39:679-681. 1996
1994 Hel-N2: a novel isoform of Hel-N1 which is conserved in rat neural tissue and produced in early embryogenesis.Gene.  151:261-265. 1994
1994 Mammalian homologs of Drosophila ELAV localized to a neuronal subset can bind in vitro to the 3' UTR of mRNA encoding the Id transcriptional repressor. 1994
1994 Autoantibodies against the Hel‐N1 RNA‐binding protein among patients with lung carcinoma: An association with type I anti–neuronal nuclear antibodiesAnnals of Neurology.  36:200-205. 1994
1993 Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAsMolecular and Cellular Biology.  13:3494-3504. 1993
1993 Hel-N1: an autoimmune RNA-binding protein with specificity for 3' uridylate-rich untranslated regions of growth factor mRNAs.Molecular and Cellular Biology.  13:3494-3504. 1993
1991 MRI reveals multiple reversible cerebral lesions in an attack of acute intermittent porphyria.Neurology.  41:1300-1302. 1991
1987 Microinjection of a benzodiazepine into substantia nigra elevates kindled seizure threshold.Brain Research.  423:261-268. 1987

Investigator On

  • Centers of Research Translation (CoRT)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Centers of Research Translation (CoRT) - Project 3  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • Dysregulation of VEGF RNA Stability in Amyotrophic Lateral Sclerosis  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Effects of Myristoylated Alanine-Rich C-Kinase Substrate on Microglial Activation  awarded by American Brain Tumor Association
  • MiR-486 is an Epigenetic Regulator of the Duchenne Muscular Dystrophy  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Negative Impact of RNA Destabilizer Tristetraprolin on Glioma Growth  awarded by National Cancer Institute/NIH/DHHS
  • Smad8 in Dystrophic Muscle Disease & Its Role in MicroRNA Regulation & Disease Progression  awarded by KAUL PEDIATRIC RESEARCH INSTITUTE
  • Smad8 is a Driver of Duchenne Muscular Dystrophy Pathology Via MyomiR Repression  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • The Impact of Normative Aging and Alzheimers Disease on Fear based Disorders and Amygdala Dysfunction  awarded by National Institute on Aging/NIH/DHHS
  • The Role of the Terminal Complement Pathway in ALS  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • UAB Research and Education Program in Neurology, Neurosurgery, and Neuropathology  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Education And Training

  • University Hospitals Case Medical Center, Internship
  • Duke University Medical Center, Residency
  • University Hospitals Case Medical Center, Residency
  • Cleveland Clinic Foundation, Postdoctoral Fellowship
  • Duke University Medical Center, Postdoctoral Fellowship
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, Duke University 1985
  • Full Name

  • Peter King